Drug Profile
Gilles de la Tourette's syndrome prodrug therapeutic - Zevra Therapeutics
Latest Information Update: 26 Feb 2023
Price :
$50
*
At a glance
- Originator KemPharm
- Developer Zevra Therapeutics
- Class Antiparkinsonians; Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gilles de la Tourette's syndrome
Most Recent Events
- 22 Feb 2023 KemPharm is now called Zevra Therapeutics
- 28 Nov 2021 No recent reports of development identified for research development in Gilles-de-la-Tourette's-syndrome(In adolescents, In children, In infants, In neonates) in USA
- 04 Oct 2017 KemPharm in-licenses nano-particulate amphetamine technology from Genco Sciences